Bristol Myers Squibb Drug Patent Portfolio
Bristol Myers Squibb owns 11 orange book drugs protected by 74 US patents with Baraclude having the least patent protection, holding only 2 patents. And Revlimid with maximum patent protection, holding 30 patents. Given below is the list of Bristol Myers Squibb's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9732062 | Therapeutically active compounds and their methods of use | 16 Sep, 2034 | Active |
| US10093654 | Therapeutically active compounds and their methods of use | 01 Aug, 2034 | Active |
| US9738625 | Therapeutically active compounds and their methods of use | 01 Aug, 2034 | Active |
| US10294215 | Therapeutically active compounds and their methods of use | 07 Jan, 2033 | Active |
| US9512107 | Therapeutically active compositions and their methods of use | 07 Jan, 2033 | Active |
| US9326945 | Apixaban formulations | 24 Feb, 2031 | Active |
| US10610125 | Methods and compositions for cell-proliferation-related disorders | 21 Jun, 2030 | Active |
| US8741929 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas | 08 Mar, 2028 | Active |
| US7465800 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | 27 Apr, 2027 | Active |
| US6967208 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 21 Nov, 2026 | Active |
| US7491725 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | 28 Sep, 2026 | Active |
| US7491725 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | 28 Mar, 2026 | Active |
| US8680103 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | 04 Aug, 2025 | Active |
| US8680103 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | 04 Feb, 2025 | Expired |
| US7855217 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | 24 Nov, 2024 | Expired |
| US7468363 | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione | 07 Oct, 2023 | Expired |
| US7968569 | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione | 07 Oct, 2023 | Expired |
| US8492406 | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | 07 Oct, 2023 | Expired |
| US7135465 | Sustained release beadlets containing stavudine | 18 Aug, 2023 | Expired |
| US8530498 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione | 15 May, 2023 | Expired |
| US8648095 | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor | 15 May, 2023 | Expired |
| US9101621 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation | 15 May, 2023 | Expired |
| US9101622 | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone | 15 May, 2023 | Expired |
| US9155730 | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent | 15 May, 2023 | Expired |
| US9393238 | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent | 15 May, 2023 | Expired |
| US7189740 | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes | 11 Apr, 2023 | Expired |
| US8404717 | Methods of treating myelodysplastic syndromes using lenalidomide | 11 Apr, 2023 | Expired |
| US9056120 | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine | 11 Apr, 2023 | Expired |
| US7135465 | Sustained release beadlets containing stavudine | 18 Feb, 2023 | Expired |
| US6596746 | Cyclic protein tyrosine kinase inhibitors | 28 Dec, 2020 | Expired |
| US7153856 | Cyclic protein tyrosine kinase inhibitors | 28 Oct, 2020 | Expired |
| US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug | 23 Oct, 2020 | Expired |
| US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated | 23 Oct, 2020 | Expired |
| US7125875 | Cyclic protein tyrosine kinase inhibitors | 13 Oct, 2020 | Expired |
| US6596746 | Cyclic protein tyrosine kinase inhibitors | 28 Jun, 2020 | Expired |
| US7153856 | Cyclic protein tyrosine kinase inhibitors | 28 Apr, 2020 | Expired |
| US7125875 | Cyclic protein tyrosine kinase inhibitors | 13 Apr, 2020 | Expired |
| US6303146 | Solid oral dosage form comprising a combination of metformin and glibenclamide | 14 Jan, 2020 | Expired |
| US6413980 | Nitrogen containing heterobicycles as factor Xa inhibitors | 22 Dec, 2019 | Expired |
| US6238695 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | 06 Oct, 2019 | Expired |
| US6555133 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | 06 Oct, 2019 | Expired |
| US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | 04 Oct, 2019 | Expired |
| US6303146 | Solid oral dosage form comprising a combination of metformin and glibenclamide | 14 Jul, 2019 | Expired |
| US6087383 | Bisulfate salt of HIV protease inhibitor | 21 Jun, 2019 | Expired |
| US6238695 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | 06 Apr, 2019 | Expired |
| US6555133 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | 06 Apr, 2019 | Expired |
| US6087383 | Bisulfate salt of HIV protease inhibitor | 21 Dec, 2018 | Expired |
| US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug | 28 Aug, 2018 | Expired |
| US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 14 Aug, 2018 | Expired |
| US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 20 Jul, 2018 | Expired |
| US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 14 Feb, 2018 | Expired |
| US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 20 Jan, 2018 | Expired |
| US5849911 | Antivirally active heterocyclic azahexane derivatives | 20 Dec, 2017 | Expired |
| US5849911 | Antivirally active heterocyclic azahexane derivatives | 20 Jun, 2017 | Expired |
| US6281230 | Isoindolines, method of use, and pharmaceutical compositions | 24 Jul, 2016 | Expired |
| US6555554 | Isoindolines, method of use, and pharmaceutical compositions | 24 Jul, 2016 | Expired |
| US7119106 | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline | 24 Jul, 2016 | Expired |
| US8288415 | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione | 24 Jul, 2016 | Expired |
| US5206244 | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines | 21 Aug, 2015 | Expired |
| US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 02 Mar, 2015 | Expired |
| US5206244 | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines | 21 Feb, 2015 | Expired |
| US5622985 | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor | 22 Oct, 2014 | Expired |
| US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 02 Sep, 2014 | Expired |
| US5622985 | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor | 22 Apr, 2014 | Expired |
| US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 21 Nov, 2013 | Expired |
| US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 21 May, 2013 | Expired |
| US5811423 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 07 Aug, 2012 | Expired |
Latest Legal Activities on Bristol Myers Squibb's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bristol Myers Squibb.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9512107 |
|
Maintenance Fee Reminder Mailed
Critical
| 11 Mar, 2024 | US9393238 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Oct, 2023 | US9326945 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Oct, 2023 | US10610125 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Mar, 2023 | US9155730 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2023 | US9101621 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2023 | US9101622 (Litigated) |
| Termination or Final Written Decision | 06 Jan, 2023 | US10610125 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Dec, 2022 | US7968569 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Nov, 2022 | US9056120 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Nov, 2022 | US10294215 |
| Petition Requesting Trial | 23 Aug, 2022 | US10610125 |
| Petition Requesting Trial | 15 Aug, 2022 | US10610125 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Jun, 2022 | US7855217 (Litigated) |
|
Correspondence Address Change
Critical
| 03 Jun, 2022 | US10610125 |
Bristol Myers Squibb's Drug Patent Litigations
Bristol Myers Squibb's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2015, against patent number US5635517. The petitioner Coalition for Affordable Drugs VI LLC, challenged the validity of this patent, with Celgene Corporation as the respondent. Click below to track the latest information on how companies are challenging Bristol Myers Squibb's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10610125 | August, 2022 |
Terminated-Settled
(06 Jan, 2023)
| Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
| US7968569 | September, 2018 |
Terminated-Denied
(14 Mar, 2019)
| Celgene Corporation | Alvogen Pine Brook LLC |
| US7189740 | August, 2018 |
Terminated-Denied
(11 Feb, 2019)
| Celgene Corporation | Dr. Reddy's Laboratories, Inc. |
| US8404717 | August, 2018 |
Terminated-Denied
(11 Feb, 2019)
| Celgene Corporation | Dr. Reddy's Laboratories, Inc |
| US9056120 | August, 2018 |
Terminated-Denied
(11 Feb, 2019)
| Celgene Corporation | Dr. Reddy's Laboratories, Inc. |
| US9326945 | April, 2018 |
Terminated-Settled
(16 Jan, 2019)
| Pfizer Inc. | Mylan Pharmaceuticals Inc. |
| US8741929 | February, 2018 |
Terminated-Denied
(27 Sep, 2018)
| Celgene Corporation | Apotex Inc. |
| US6045501 | April, 2015 |
Final Written Decision
(26 Oct, 2016)
| Celgene Corporation | Coalition For Affordable Drugs VI LLC |
| US6315720 | April, 2015 |
FWD Entered
(26 Oct, 2016)
| Celgene Corporation | Coalition for Affordable Drugs VI LLC |
| US6967208 | August, 2015 |
Terminated-Denied
(22 Feb, 2016)
| Bristol-Myers Squibb Company | Coalition for Affordable Drugs IX, LLC |
| US5635517 | May, 2015 |
Terminated-Denied
(16 Nov, 2015)
| Celgene Corporation | Coalition for Affordable Drugs VI LLC |
Bristol Myers Squibb Drug Patents' Oppositions Filed in EPO
Bristol Myers Squibb drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 29, 2010, by Apotex Inc.. This opposition was filed on patent number EP05722772A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17175864A | Aug, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Intas Pharmaceuticals Ltd. | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Wittkopp, Alexander | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | von Seebach, Malte | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Kutzenberger Wolff & Partner | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Zentiva k.s. | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Teva Pharmaceutical Industries LTD. | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | Krka, d.d., Novo mesto | Granted and Under Opposition |
| EP17175864A | Aug, 2020 | SANDOZ AG | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Intas Pharmaceuticals Ltd. | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | KRKA, d.d., Novo mesto | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Sandoz AG | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Sandoz AG | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | KRKA, d.d., Novo mesto | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Intas Pharmaceuticals Ltd. | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Medichem S.A. | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Medichem S.A. | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Kutzenberger Wolff & Partner | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Zentiva k.s. | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | Kutzenberger Wolff & Partner | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | Zentiva k.s. | Granted and Under Opposition |
| EP17178613A | Jul, 2020 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP17175788A | Jul, 2020 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP15190823A | Sep, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15190823A | Sep, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP15190823A | Sep, 2019 | Zentiva, k.s. | Granted and Under Opposition |
| EP15190823A | Sep, 2019 | Intas Pharmaceuticals Ltd. | Granted and Under Opposition |
| EP15190823A | Sep, 2019 | KRKA, d.d., Novo mesto | Granted and Under Opposition |
| EP15190823A | Sep, 2019 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP15190823A | Aug, 2019 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP15190823A | Aug, 2019 | Sandoz AG | Granted and Under Opposition |
| EP15190823A | Aug, 2019 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP15199526A | Aug, 2019 | Generics [UK] Ltd | Revoked |
| EP15199540A | Aug, 2019 | Generics (UK) Ltd | Revoked |
| EP15199521A | Aug, 2019 | Hamm&Wittkopp Patentanwälte PartmbB | Revoked |
| EP15199521A | Aug, 2019 | Bachelin, Martin, Dr. | Revoked |
| EP15199521A | Aug, 2019 | Generics [UK] Ltd | Revoked |
| EP15199521A | Jul, 2019 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Revoked |
| EP15199521A | Jul, 2019 | Pruß, Timo | Revoked |
| EP11707284A | Sep, 2016 | Zentiva k.s. | Revoked |
| EP11707284A | Sep, 2016 | LEK Pharmaceuticals d.d. | Revoked |
| EP11707284A | Sep, 2016 | Intas Pharmaceuticals Ltd. | Revoked |
| EP11707284A | Sep, 2016 | Hamm&Wittkopp Patentanwälte PartmbB | Revoked |
| EP11707284A | Sep, 2016 | Generics (U.K.) Limited | Revoked |
| EP11707284A | Sep, 2016 | Galenicum Health S.L. | Revoked |
| EP11707284A | Sep, 2016 | KRKA, d.d., Novo mesto | Revoked |
| EP11707284A | Sep, 2016 | STADA Arzneimittel AG | Revoked |
| EP11707284A | Sep, 2016 | Plougmann Vingtoft a/s | Revoked |
| EP11707284A | Sep, 2016 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Revoked |
| EP11707284A | Sep, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP09008756A | Jul, 2015 | Accord Healthcare Ltd | Revoked |
| EP09008756A | Jul, 2015 | Hexal AG | Revoked |
| EP09008756A | Jul, 2015 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP09008756A | Jul, 2015 | Intellectual Property Services | Revoked |
| EP09008756A | Jul, 2015 | Synthon B.V. | Revoked |
| EP09008756A | Jul, 2015 | Actavis Group PTC EHF | Revoked |
| EP04783095A | Aug, 2012 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP04783095A | Aug, 2012 | Generics [UK] Limited | Revoked |
| EP03728969A | Dec, 2010 | STRAWMAN LIMITED | Revoked |
| EP03728969A | Nov, 2010 | Synthon B.V. | Revoked |
| EP05722772A | Sep, 2010 | Gallafent, Antony Xavier | Patent maintained as amended |
| EP05722772A | Sep, 2010 | APOTEX INC. | Patent maintained as amended |
Bristol Myers Squibb's Family Patents
Bristol Myers Squibb drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 22.9% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Bristol Myers Squibb Drug List
Given below is the complete list of Bristol Myers Squibb's drugs and the patents protecting them.
1. Baraclude
Baraclude is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5206244
(Pediatric)
| Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
21 Aug, 2015
(9 years ago)
| Expired |
| US5206244 | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
21 Feb, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baraclude's drug page
2. Eliquis
Eliquis is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9326945 | Apixaban formulations |
24 Feb, 2031
(5 years from now)
| Active |
| US6967208 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
21 Nov, 2026
(1 year, 5 months from now)
| Active |
| US6413980 | Nitrogen containing heterobicycles as factor Xa inhibitors |
22 Dec, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eliquis's drug page
3. Glucovance
Glucovance is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6303146
(Pediatric)
| Solid oral dosage form comprising a combination of metformin and glibenclamide |
14 Jan, 2020
(5 years ago)
| Expired |
| US6303146 | Solid oral dosage form comprising a combination of metformin and glibenclamide |
14 Jul, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucovance's drug page
4. Idhifa
Idhifa is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9732062 | Therapeutically active compounds and their methods of use |
16 Sep, 2034
(9 years from now)
| Active |
| US10093654 | Therapeutically active compounds and their methods of use |
01 Aug, 2034
(9 years from now)
| Active |
| US9738625 | Therapeutically active compounds and their methods of use |
01 Aug, 2034
(9 years from now)
| Active |
| US10294215 | Therapeutically active compounds and their methods of use |
07 Jan, 2033
(7 years from now)
| Active |
| US9512107 | Therapeutically active compositions and their methods of use |
07 Jan, 2033
(7 years from now)
| Active |
| US10610125 | Methods and compositions for cell-proliferation-related disorders |
21 Jun, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Idhifa's drug page
5. Pravachol
Pravachol is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5622985
(Pediatric)
| Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
22 Oct, 2014
(10 years ago)
| Expired |
| US5622985 | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
22 Apr, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pravachol's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Pravigard Pac (copackaged)
Pravigard Pac (copackaged) is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5622985
(Pediatric)
| Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
22 Oct, 2014
(10 years ago)
| Expired |
| US5622985 | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
22 Apr, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pravigard Pac (copackaged)'s drug page
7. Revlimid
Revlimid is protected by 30 patents, out of which 28 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8741929 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
08 Mar, 2028
(2 years from now)
| Active |
| US7465800 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
27 Apr, 2027
(1 year, 10 months from now)
| Active |
| US7855217 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
24 Nov, 2024
(6 months ago)
| Expired |
| US7468363 | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
07 Oct, 2023
(1 year, 7 months ago)
| Expired |
| US7968569 | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
07 Oct, 2023
(1 year, 7 months ago)
| Expired |
| US8492406 | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
07 Oct, 2023
(1 year, 7 months ago)
| Expired |
| US8530498 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
15 May, 2023
(2 years ago)
| Expired |
| US8648095 | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
15 May, 2023
(2 years ago)
| Expired |
| US9101621 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
15 May, 2023
(2 years ago)
| Expired |
| US9101622 | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
15 May, 2023
(2 years ago)
| Expired |
| US9155730 | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
15 May, 2023
(2 years ago)
| Expired |
| US9393238 | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
15 May, 2023
(2 years ago)
| Expired |
| US7189740 | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
11 Apr, 2023
(2 years ago)
| Expired |
| US8404717 | Methods of treating myelodysplastic syndromes using lenalidomide |
11 Apr, 2023
(2 years ago)
| Expired |
| US9056120 | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
11 Apr, 2023
(2 years ago)
| Expired |
| US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
23 Oct, 2020
(4 years ago)
| Expired |
| US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
23 Oct, 2020
(4 years ago)
| Expired |
| US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
04 Oct, 2019
(5 years ago)
| Expired |
| US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
28 Aug, 2018
(6 years ago)
| Expired |
| US6281230 | Isoindolines, method of use, and pharmaceutical compositions |
24 Jul, 2016
(8 years ago)
| Expired |
| US6555554 | Isoindolines, method of use, and pharmaceutical compositions |
24 Jul, 2016
(8 years ago)
| Expired |
| US7119106 | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
24 Jul, 2016
(8 years ago)
| Expired |
| US8288415 | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
24 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Revlimid's drug page
8. Reyataz
Reyataz is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6087383
(Pediatric)
| Bisulfate salt of HIV protease inhibitor |
21 Jun, 2019
(5 years ago)
| Expired |
| US6087383 | Bisulfate salt of HIV protease inhibitor |
21 Dec, 2018
(6 years ago)
| Expired |
| US5849911
(Pediatric)
| Antivirally active heterocyclic azahexane derivatives |
20 Dec, 2017
(7 years ago)
| Expired |
| US5849911 | Antivirally active heterocyclic azahexane derivatives |
20 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyataz's drug page
9. Sprycel
Sprycel is protected by 10 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7491725
(Pediatric)
| Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
28 Sep, 2026
(1 year, 3 months from now)
| Active |
| US7491725 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
28 Mar, 2026
(9 months from now)
| Active |
| US8680103
(Pediatric)
| Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
04 Aug, 2025
(2 months from now)
| Active |
| US8680103 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
04 Feb, 2025
(3 months ago)
| Expired |
| US6596746
(Pediatric)
| Cyclic protein tyrosine kinase inhibitors |
28 Dec, 2020
(4 years ago)
| Expired |
| US7153856
(Pediatric)
| Cyclic protein tyrosine kinase inhibitors |
28 Oct, 2020
(4 years ago)
| Expired |
| US7125875
(Pediatric)
| Cyclic protein tyrosine kinase inhibitors |
13 Oct, 2020
(4 years ago)
| Expired |
| US6596746 | Cyclic protein tyrosine kinase inhibitors |
28 Jun, 2020
(4 years ago)
| Expired |
| US7153856 | Cyclic protein tyrosine kinase inhibitors |
28 Apr, 2020
(5 years ago)
| Expired |
| US7125875 | Cyclic protein tyrosine kinase inhibitors |
13 Apr, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sprycel's drug page
10. Sustiva
Sustiva is protected by 13 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6238695
(Pediatric)
| Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
06 Oct, 2019
(5 years ago)
| Expired |
| US6555133
(Pediatric)
| Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
06 Oct, 2019
(5 years ago)
| Expired |
| US6238695 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
06 Apr, 2019
(6 years ago)
| Expired |
| US6555133 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
06 Apr, 2019
(6 years ago)
| Expired |
| US6639071
(Pediatric)
| Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
14 Aug, 2018
(6 years ago)
| Expired |
| US6939964
(Pediatric)
| Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
20 Jul, 2018
(6 years ago)
| Expired |
| US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
14 Feb, 2018
(7 years ago)
| Expired |
| US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
20 Jan, 2018
(7 years ago)
| Expired |
| US5663169
(Pediatric)
| Benzoxazinones as inhibitors of HIV reverse transcriptase |
02 Mar, 2015
(10 years ago)
| Expired |
| US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
02 Sep, 2014
(10 years ago)
| Expired |
| US5519021
(Pediatric)
| Benzoxazinones as inhibitors of HIV reverse transcriptase |
21 Nov, 2013
(11 years ago)
| Expired |
| US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
21 May, 2013
(12 years ago)
| Expired |
| US5811423 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
07 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sustiva's drug page
11. Zerit Xr
Zerit Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7135465
(Pediatric)
| Sustained release beadlets containing stavudine |
18 Aug, 2023
(1 year, 9 months ago)
| Expired |
| US7135465 | Sustained release beadlets containing stavudine |
18 Feb, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zerit Xr's drug page